Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 12, 2016. The document serves as a transaction notification regarding a purchase of ordinary shares by a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a regulatory disclosure of a specific share transaction rather than a financial performance report.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of ordinary shares under ShareReward Plan |
| Instrument | Ordinary shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Price | £16.7127 per share |
| Volume Acquired | 14 Ordinary shares (7 partnership shares + 7 matching shares) |
| Transaction Date | July 11, 2016 (12:18 GMT) |
| Exchange | London Stock Exchange (XLON) |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely documents an initial notification of a share acquisition by Mrs. V A Whyte, the Company Secretary.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a standard compliance notification under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- The transaction involves the Company Secretary, Mrs. V A Whyte, acquiring shares under the company's ShareReward Plan.
- The total volume of 14 shares was acquired at a price of £16.7127 per share.
- The transaction occurred on the London Stock Exchange on July 11, 2016.
- This filing does not contain financial performance data; investors should refer to Form 20-F for comprehensive financial results.